NCT00372437View on ClinicalTrials.gov

A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Tumors
Interventions
DRUG

MGCD0103

MGCD0103 as an oral dose three times per week.

DRUG

Gemcitabine

Gemcitabine 1000mg/m\<2\> intravenously days 1, 8, 15 of a 28 day cycle.

Trial Locations (8)

27710

Duke University Medical Center, Durham

44718

Gabrail Cancer Center, Canton

46202

Indiana University Cancer Center, Indianapolis

64128

Veterans Affairs Medical Center, Kansas City

19104-4283

Pennsylvania Presbyterian Medical Center, Philadelphia

37232-6307

Vanderbilt University Medical Center, Nashville

H2W 1S6

McGill University/Dept Oncology, Montreal

J1H 5N4

CHUS Hopital Fleurimont, Sherbrooke

Sponsors
All Listed Sponsors
lead

Mirati Therapeutics Inc.

INDUSTRY

NCT00372437 - A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine | Biotech Hunter | Biotech Hunter